<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00703573</url>
  </required_header>
  <id_info>
    <org_study_id>0721D1424</org_study_id>
    <nct_id>NCT00703573</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 2 Doses of S-777469 in Patients With Atopic Dermatitis</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of 2 Doses of S-777469 (400 mg BID and 800 mg BID) in Patients With Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shionogi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shionogi Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of 2 doses of S-777469 in
      patients with atopic dermatitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of S-777469 was assessed by Physician's Global Assessment (PGA) and Numerical Rating Scale (NRS)</measure>
    <time_frame>Change from baseline to 12 weeks</time_frame>
    <description>Physician's Global Assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety was assessed by repeated clinical evaluation and evaluation of treatment-emergent adverse events. It included vital signs, medical history, concomitant medications, physical examination, 12-lead ECGs, and standard clinical laboratory safety tests</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Safety, determined by Adverse event frequency and changes in laboratory values</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy was assessed by PGA, NRS, Behavioral Rating Scale, Eczema Area and Severity Index Score, Investigator panel treatment-blind comparative review ratings of digital photography of affected areas, and Thymus and Activation-Regulated Chemokine</measure>
    <time_frame>Changes from baseline to various pre-defined time-points during the 12 week study</time_frame>
    <description>Assessment of PGA, NRS, Behavioral Rating Scale, Eczema Area and Severity Index Score, Investigator panel treatment-blind comparative review ratings of digital photography of affected areas, and Thymus and Activation-Regulated Chemokine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic analysis of the concentration of unchanged parent drug (S-777469) in trough samples</measure>
    <time_frame>From Baseline during Week 1</time_frame>
    <description>The concentration of S-777469 will be evaluated to determine when steady state is achieved</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">209</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>S-777469 400 mg BID (two 200 mg tablets of S-777469 and two tablets of placebo BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>S-777469 800 mg BID (four 200 mg tablets of S-777469 BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo BID (four tablets of placebo BID)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-777469 400 mg</intervention_name>
    <description>S-777469 400 mg BID</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-777469 800 mg</intervention_name>
    <description>S-777469 800 mg BID</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo BID</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Screening Inclusion Criteria:

        Each patient must meet all of the following inclusion criteria to be screened and enrolled
        into the single-blind period:

          -  Males or females between 18 and 65 years of age at the time of obtaining the written
             informed consent

          -  Patient understands the study procedures and agrees to participate in the study by
             giving written informed consent

          -  Patient agrees to allow digital photographs of atopic dermatitis (AD)-affected target
             areas during the study

          -  Patient satisfies the diagnostic criteria for AD as defined by the criteria of Hanifin
             and Rajka (Acta Derm Venereol.1980;92[suppl]:44-47; J Am Acad
             Dermatol.2003;49[6]:1088-1095), as follows:

        Must have 3 or more basic features:

          -  Pruritis

          -  Typical morphology and distribution: flexural lichenification or linearity

          -  Chronic or chronically relapsing dermatitis

          -  Personal or family history of atopy (asthma, allergic rhinitis, atopic dermatitis)

        Plus 3 or more minor features:

          -  Xerosis

          -  Ichthyosis/palmar hyperlinearity/keratosis pilaris

          -  Early age of onset

          -  Tendency toward cutaneous infections (esp. Staphylococcus aureus and Herpes simplex)
             /impaired cell-mediated immunity

          -  Tendency toward non-specific hand or foot dermatitis

          -  Nipple eczema

          -  Cheilitis

          -  Recurrent conjunctivitis

          -  Dennie-Morgan infraorbital fold

          -  Keratoconus

          -  Anterior subcapsular cataracts

          -  Orbital darkening

          -  Facial pallor/facial erythema

          -  Pityriasis alba

          -  Anterior neck folds

          -  Itch when sweating

          -  Intolerance to wool and lipid solvents

          -  Perifollicular accentuation

          -  Food intolerance

          -  Course influenced by environmental/emotional factors

          -  White dermographism/delayed blanch

          -  Immediate (type I) skin test reactivity (Provide test results within one year of
             Screening date.)

          -  Elevated serum IgE.

               -  Patient has negative laboratory results for hepatitis B surface antigen and IgG
                  anti- Hepatitis B core, hepatitis C virus antibodies, and human immunodeficiency
                  virus (HIV) antibody tests at screening

               -  Serum creatinine and blood urea nitrogen are in the normal range at screening

               -  Female patients of child bearing potential must have a negative pregnancy test at
                  screening and Day-14

               -  Patient has a negative screen for drugs of abuse at screening

               -  Patient does not have a history or clinical manifestations of significant
                  metabolic, hepatic, renal, hematological, pulmonary, cardiovascular,
                  gastrointestinal or urological disease

               -  Patient does not have liver function test results &gt;1.25 the upper limit of normal
                  NOTE: Under no circumstances should a patient who did not qualify regarding liver
                  function tests (alanine aminotransferase [ALT] and/or aspartate aminotransferase
                  [AST]) be re-screened and/or re-qualified

               -  Patient does not have QTc &gt; 450 (males) or &gt; 470 (females) at screening

        Randomization Inclusion Criteria:

        Patients eligible to be randomized to double-blind treatment must satisfy all of the
        following inclusion criteria:

          -  Patient has all of the following at the end of the single-blind period (Day 1, just
             before randomization to study drug):

               -  Physician's Global Assessment (PGA) ≥ 2 but ≤ 4.

               -  The average of the scores recorded from the evening of Day -3 to the morning of
                  Day 1 (Baseline value) of the Numerical Rating Scale (NRS) is ≥ 4.

               -  The average of the scores recorded from the evening of Day -3 to the morning of
                  Day 1 (Baseline value) of the Behavior Rating Scale (BRS) is ≥ 2

          -  Patient has negative laboratory results for hepatitis B surface antigen, IgE
             anti-Hepatitis B core, hepatitis C virus antibodies, and HIV antibody tests at
             screening

          -  Female patients of child bearing potential must have a negative pregnancy test at
             screening, single-blind period (Day-14) and baseline (Day 1)

          -  Serum creatinine and blood urea nitrogen are in the normal range at screening

          -  Patient has negative screen for drugs of abuse at screening and single-blind (Day-14)

          -  Use of adequate birth control by men and women, if of reproductive potential and
             sexually active. Adequate birth control is defined as agreement to consistently
             practice an effective and accepted method of contraception throughout the duration of
             the study and for 2 weeks after the last dose of study drug

               -  For females, adequate birth control methods will be defined as: hormonal
                  contraceptives, intrauterine device or double barrier contraception, i.e., condom
                  + diaphragm, condom or diaphragm + spermicidal gel or foam

               -  For males adequate birth control methods will be defined as double barrier
                  contraception, i.e., condom + diaphragm, condom or diaphragm + spermicidal gel or
                  foam

               -  For females, menopause is defined as one year without menses; if in question, a
                  follicle-stimulating hormone of &gt;40 U/ml must be documented. Hysterectomy,
                  bilateral oophorectomy, or bilateral tubal ligation must be documented, as
                  applicable

          -  Patient has not used any treatments for AD prior to Day 1, using the following time
             periods:

               -  Systemic (inhaled, oral, suppository or immediate release injectable, depot or
                  sustained-release injectable) corticosteroids, cytostatic drugs, or other
                  immunosuppressant drugs: 5 weeks prior to Day 1

               -  Topical immunosuppressant drugs: 4 weeks prior to Day 1

               -  Phototherapy, specific desensitization therapy, nonspecific disease-modulating
                  therapy and elimination diet therapy: 4 weeks prior to Day 1

               -  Any drugs that are known inhibitors or inducers of Cytochrome P450 isozyme
                  cytochrome CYP2C9: 2 weeks prior to Day 1

               -  Systemic antibiotics: 4 weeks prior to Day 1

               -  Topical steroids or tar preparations: 2 weeks prior to Day 1

               -  Antihistamines, histamine-added γ-globulin preparations, desensitization therapy,
                  or other nonspecific disease-modifying therapies: 2 weeks prior to Day 1

               -  Herbal preparation, cosmetic or emollient preparations other than those issued
                  during the screening and single-blind periods: 2 weeks prior to Day 1. Use of
                  cosmetic make-up will be allowed

               -  Acetaminophen, acetaminophen-containing products, or non-steroidal
                  anti-inflammatories: 2 weeks prior to Day 1

               -  Any other investigational drug or device within 8 weeks prior to Day 1

          -  Patient is willing to completely avoid the use of any prescription or nonprescription
             treatments for AD , including over-the-counter drugs or any topical preparations,
             other than those topical emollient preparations provided by the study site during the
             screening period and thereafter, as needed. Use of hormone replacement therapy (for
             postmenopausal females) and/or use of hormonal contraceptive(s), intrauterine device,
             or double barrier contraception, i.e., condom + diaphragm, condom or diaphragm +
             spermicidal gel or foam will be allowed. Use of topical antibiotics will be allowed
             during the study

        Exclusion Criteria:

        Patients satisfying any of the following exclusion criteria are not eligible for enrollment
        into the double-blind treatment period:

          -  Patient is under the age of legal consent, is mentally or legally incapacitated and/or
             has significant emotional problems at the time of study entry

          -  Patient has an active dermatologic condition other than AD which may confound the
             diagnosis or evaluation of AD, such as scabies, allergic contact dermatitis,
             seborrheic dermatitis, cutaneous lymphoma, or psoriasis

          -  Patient has a history of malignancy not in remission for &gt;5 years, with the exception
             of cutaneous basal cell carcinoma and cutaneous squamous cell carcinoma

          -  Presence of comorbid conditions that would preclude participation in the study,
             including:

               -  Immune compromised state, including recent chemotherapy, immunotherapy, or organ
                  transplant

               -  History or clinical manifestations of significant metabolic, hepatic, renal,
                  hematological, pulmonary, cardiovascular, gastrointestinal or urological disease

               -  Signs and symptoms of eczema herpeticum within the preceding 12 months or
                  cellulitis within preceding 3 months

               -  Positive results for HIV infection at screening

               -  History or clinical manifestations of significant neurological (e.g., epilepsy)
                  or psychiatric disorders (e.g., history of suicide attempt; history of
                  psychiatric episodes resulting in hospitalization)

               -  An active intercurrent infection

               -  History of clinically significant hypersensitivity, anaphylaxis, or allergies to
                  any drug compound, which resulted in a severe adverse event

               -  Liver function tests (ALT, AST) &gt;1.25 times the upper limit of normal at
                  Screening. (refer to Covance Lab Manual for reference ranges) Note: Under no
                  circumstances should a patient who did not qualify regarding liver function tests
                  (ALT and/or AST) be re-screened and/or re-qualified

          -  Patient has any acute or chronic condition or prior therapy that, in the opinion of
             the Investigator, would limit the patient's ability to complete and/or participate in
             this clinical study or otherwise would make the patient unsuitable for this study

          -  Patient has a history of drug abuse within 1 year prior to Day 1

          -  Patient consumes excess amounts of alcohol, defined as exceeding an average of 14
             drinks/week (1 drink = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of hard
             liquor, or any combination of them) within 2 months prior to Day -14 (beginning of
             single-blind period) or is unwilling to comply with the restricted use of alcohol (as
             defined above, no more than 14 drinks/week) from screening, throughout the study, and
             until study completion (follow-up visit).

          -  Patient uses any prohibited concomitant medications at any time during the study

          -  Patient is pregnant or lactating or intends to become pregnant or, in the case of a
             male patient, intends to father a child during the study period and for 2 weeks after
             the last dose of study medication

          -  Patient has poor peripheral venous access that may limit blood sampling for clinical
             laboratory or pharmacokinetic analysis

          -  Patient has participated in any other investigational study drug or device trial in
             which receipt of an investigational study drug or device occurred within 8 weeks prior
             to Day 1

          -  Prior exposure to S-777469

          -  Any reason which, in the opinion of the Investigator, interferes with the ability of
             the patient to participate in or complete the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shionogi Clinical Trials Administrator Clinical Support Help Line</last_name>
    <role>Study Director</role>
    <affiliation>Shionogi</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alpharetta</city>
        <state>Georgia</state>
        <zip>30022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paramus</city>
        <state>New Jersey</state>
        <zip>07652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lake Oswego</city>
        <state>Oregon</state>
        <zip>97035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>973239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johnston</city>
        <state>Rhode Island</state>
        <zip>02919</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goodlettsville</city>
        <state>Tennessee</state>
        <zip>37072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37934</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2008</study_first_submitted>
  <study_first_submitted_qc>June 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2008</study_first_posted>
  <disposition_first_submitted>April 26, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>April 26, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">May 1, 2018</disposition_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atopic Dermatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

